855249-76-2

Upstream product

• 855249-74-0 trans (3R,5S)-7-[5-(3-dimethylcarbamoylphenylcarbamoyl)-3,4-bis-(4-fluorophenyl)-1-isopropyl-1H-pyrrolyl]-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 855248-38-3 3,4-bis-(4-fluoro-phenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid 
• 1027038-69-2 C₂₁H₁₆ClF₂NO₂ 
• 126209-32-3 3,4-bis-(4-fluorophenyl)-1H-pyrrole-2-carboxylic acid ethyl ester 
• 126209-33-4 3,4-bis-(4-fluorophenyl)-1-isopropyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 855248-37-2 3,4-bis-(4-fluorophenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 855249-68-2 3,4-bis-(4-fluorophenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid (3-dimethylcarbamoylphenyl)amide 
• 950599-02-7 C₄₃H₅₁F₂N₃O₆Si 
• 950599-55-0 C₃₇H₃₇F₂N₃O₆ 
• 1535-41-7 1-fluoro-4-(nitromethyl)benzene 
• 459-57-4 4-fluorobenzaldehyde 
• 459-46-1 4-Fluorobenzyl bromide 

Relevant academic research and scientific papers

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors

This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting i

N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS

HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided. Formula (I).